The Giants Have Lost Their Whole Infield and Willy Adames Is the Latest

San Francisco placed Willy Adames on the 10-day injured list this week with a sprained left elbow, and the diagnosis that followed was worse than the initial designation suggested. Adames has been diagnosed with a sprain of the ulnar collateral ligament, sustained sliding home in the first inning of the series finale against Boston. Because the injury is to his non-throwing arm, the club has not made a determination on surgery, and it is not clear whether he returns this season.

That is the third infield regular San Francisco has lost. Matt Chapman underwent season-ending surgery earlier this month for a core muscle injury, with the procedure performed in Philadelphia by a specialist who confirmed the tear. Reporting on the surgery described the core muscle having torn off the pubic bone on both sides, requiring reattachment. Casey Schmitt, who had been the club's most productive hitter by rate statistics before his own injury, tore his meniscus and is likely finished for the year.

How the Giants got here

Chapman's season was a slow-motion collapse. He suffered an abdominal strain during a series at Cincinnati in mid-April and tried to play through it for weeks before finally landing on the injured list on July 1. He batted .235 with seven home runs and 42 RBIs over 84 games before the surgery. Reports indicate he spent roughly eight to 12 weeks rehabbing and is expected to have a normal offseason and be ready for 2027, which is the only good news in the sequence. He is signed through 2030 on a six-year contract.

Schmitt was the counterweight. With Chapman out for July, Schmitt played third base every day and hit well enough to be the club's best regular by OPS. The Giants had him under club control for years and were planning to install him at second base long term. The meniscus tear ended that season.

Adames was the last of the three standing, and now he is not.

Fantasy fallout

The immediate action item is that Adames should be dropped in almost all redraft formats. A UCL sprain with no return timeline, on a team that is not in a position to rush anybody back, in the last week of August, is not a stash worth a roster spot with fantasy playoffs approaching. In deep leagues with IL slots, hold him. Everywhere else, move on.

Chapman has been droppable for weeks and Schmitt is in the same category.

The upside is on the replacement side, and it is thinner than it looks. Christian Koss has been the name filling in at third base during Chapman's absences, and the Giants have cycled through internal options rather than making a significant external addition. None of the available replacements profile as a difference-maker in a standard 12-team mixed league. In NL-only and deep leagues, the playing time itself is worth something, and whoever settles into the everyday shortstop role for the final month has value purely on volume.

Rafael Devers is the Giants hitter whose value is most affected in the other direction. With three infield regulars gone, the lineup around him thins considerably, which suppresses his RBI opportunities and his runs scored. He remains a must-start, but the counting-stat environment is materially worse than it was in June.

The betting angle

San Francisco's run-scoring projection has to come down, and the market has been slow to fully reflect the cumulative effect of three infielders. Individual injury news moves a team total by a fraction of a run. Three of them, compounding, changes what the lineup actually is.

Our model now projects the Giants among the bottom third of the league in runs per game for the remainder of the season, which is a meaningful shift from where they graded in July. The most actionable expression of that is on Giants team totals, where our projected number sits below the market on most nights, and on opposing starting pitcher strikeout props, where a lineup with this many replacement-level bats is a friendlier matchup than the market price implies.

The Giants' playoff odds in our model have fallen accordingly. Losing three infield regulars in a season where the club's offensive core was already underperforming is the kind of compounding damage that a September run does not usually overcome.

The Verdexed model take

Our projection system treats position-player injuries by redistributing plate appearances to the actual replacements rather than applying a generic team penalty, and that method is why the Giants' revised outlook is more pessimistic than most published adjustments. The replacements here are not average major league hitters. They are organizational depth pieces getting everyday at-bats in a pennant race they are unlikely to win.

For daily fantasy, the Giants lineup is now a fade in cash games and a leverage play only in specific park and matchup conditions. The individual Giants worth rostering are Devers and, on days he is in the lineup against a favorable handedness matchup, whoever is playing every day in the middle infield.

What's next

The Giants will need to make a determination on whether Adames requires surgery, and that decision will be the first hard information about his 2027 availability as well as the rest of this season. A UCL in a non-throwing elbow is a different problem than a pitcher's UCL, and the treatment path is less standardized.

For fantasy managers, the practical takeaway is simpler. This lineup is not a source of production for the rest of 2026, the replacement options are not worth chasing in mixed leagues, and the most useful thing to do with the news is to fade San Francisco's offense in every format where fading an offense is possible.